|Patients with Relapsed / Refractory Follicular Lymphoma may Benefit from a Reduced-Intensity Allogeneic Transplant
||Auto transplant or reduced-intensity allo transplant can help patients with follicular lymphoma.
More than 2 years after transplant, patients who get an allo transplant are more likely to survive than patients who get an auto transplant.
|Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors.|
|Individualized Care Plans for Transplant Recipients: An Example of Patient-Centered Research
||Patients are involved in every step of the research process.
Researchers think the care plans will help patients be healthier and less stressed after transplant.
|Patient centeredness and engagement in quality-of-care oncology research.|
|National Survey of Transplant Center Resources, Staff, and Structure
||Different transplant centers have different resources, staff, and structure.
||National survey of hematopoietic cell transplantation center personnel, infrastructure, and models of care delivery.|
|Bone Marrow Donors have more Side Effects at Hospitals that do Fewer Bone Marrow Collections
||Bone marrow donors had more side effects at hospitals that did fewer bone marrow collections.
||An analysis of the effect of race, socioeconomic status and center size on unrelated NMDP donor outcomes: donor toxicities are more common at low volume bone marrow collection centers.|
|Transplant can help some Children with Hypodiploid Acute Lymphoblastic Leukemia
||Children with hypodiploid ALL did worse when they had a transplant later (in their 2nd complete remission).
Children with 43 or fewer chromosomes in their diseased cells had a higher risk of the leukemia coming back and dying after transplant compared to children with 44 or 45 chromosomes.
While more children may live longer because doctors can find better matched donors, disease factors still affect transplant outcomes.
|Transplant outcomes for children with hypodiploid acute lymphoblastic leukemia.|
|A New way to Measure Acute Graft-Versus-Host Disease can Help Doctors Predict Transplant Outcomes
||The Refined Acute GVHD Risk Score is a way for doctors to predict the likelihood that:
A patient will be alive 6 months after starting treatment for acute GVHD.
Acute GVHD will get better with steroids.
|A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.|
|New Blood Test can Predict the Severity of Acute Graft-Versus-Host Disease
||Biomarkers can predict whether acute GVHD will be mild or severe and whether it is likely to respond to treatment.
||A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.|
|Patients with Myeloma or Lymphoma can have Excellent Outcomes After an Outpatient Autologous Transplant
||Outcomes (results) were similar in the inpatient and outpatient transplant groups.
||Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.|
|Allogeneic Transplant may be a Good Treatment Option for Patients 40 Years or Older with Non-Hodgkin Lymphoma
||Reduced-intensity transplant may help patients who are 40 years or older and have NHL.
The chance of getting GVHD did not depend on the patient's age.
|Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. |
|Guidelines on Cancer Screening for Transplant Recipients
||Common places for new cancers after transplant are the mouth, skin, breast, and thyroid.
Both allogeneic and autologous transplant recipients have a higher chance of getting a new cancer.
|Secondary solid cancer screening following hematopoietic cell transplantation.|
|Guidelines for Transplant and Multiple Myeloma
||Doctors should consider recommending an autologous transplant for most patients with multiple myeloma.
||Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the ASBMT.|
|Fertility Preservation Options Before Transplant
||Tell your doctor right away if you want to talk about fertility preservation.
||Clinical guide to fertility preservation in hematopoietic cell transplant recipients.|
|Patients with Lymphoma have Similar Survival After Transplant Whether the Unrelated Donor is Matched, Mismatched, or Cord Blood
||3-year survival was about the same no matter what type of unrelated donor a patient had: matched, mismatched, or cord blood.
||Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.|
|More Patients who have a Transplant from an Unrelated Donor Survive than in the Past
||3-year survival after transplant from an unrelated donor has increased over time.
||Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era.|
|More Teens and Young Adults with ALL Survive After Blood or Marrow Transplant than in the Past
||5-year survival increased over time in teens and young adults and in children.
||Survival improvements in adolescents and young adults after myeloblative allogeneic transplantation for acute lymphoblastic leukemia.|